- The plant, which has a surface area of 400m2, will serve both Sylentis’ manufacturing needs and those of other pharmaceutical companies.
Madrid, April 19th, 2022. – Sylentis, a wholly owned subsidiary of PharmaMar (MSE:PHM), today inaugurated the first plant in Spain and the third in Europe for the manufacture of oligonucleotides approved under GMP (Good Manufacture Practice) standards at the Madrid Technology Park in Tres Cantos. Oligonucleotides are short chains of DNA or RNA that are manufactured by chemical synthesis and are the active ingredient of a new class of drugs.
This plant is already functioning to meet the needs of both tivanisiran and SYL1801. These products, owned by Sylentis, are based on RNA interference technology. Tivanisiran is currently being evaluated in two Phase III studies for the treatment of dry eye disease and SYL1801, for the treatment of age-related macular degeneration.
This plant, a pioneer in Spain, plans to provide services to other pharmaceutical companies that require the manufacturing and analysis of oligonucleotides.
Currently, the demand for drugs based on RNA technologies is increasing and in Spain this need has not been met internally, depending instead on other countries.
“This first plant in Spain is a milestone, not only for Sylentis, but also for the pharmaceutical industry in our country, as it will have the capacity to produce this type of next-generation pharmaceuticals, with the aim of making them available to patients to cover their therapeutic needs that have not been met so far,” said Ana Isabel Jiménez, Director of Executive Operations and R&D at Sylentis.
The inauguration was attended by Cristobal Belda Iniesta, General Manager of the Instituto de Salud Carlos III; Ana Isabel Cremades Rodríguez, General Manager of Research and Innovation and Technology of the Community of Madrid; Jesús Moreno García, Mayor of Tres Cantos; Ion Arocena, General Manager of ASEBIO, accompanied by José María Fernández, President of PharmaMar; Luis Mora, Managing Director of the PharmaMar’s Oncology and Virology Business Units and Ana Isabel Jiménez, Director of Executive Operations and R&D at Sylentis.
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare outcomes of patients afflicted by serious diseases with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. PharmaMar intends to continue to be the world leader in marine medicinal discovery, development and innovation.
PharmaMar has developed and now commercializes Yondelis® in Europe by itself, as well as Zepzelca® (lurbinectedin), in the US; and Aplidin® (plitidepsin), in Australia, with different partners. In addition, it has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar has other clinical-stage programs under development for several types of solid cancers: lurbinectedin and ecubectedin. Headquartered in Madrid (Spain), PharmaMar has subsidiaries in Germany, France, Italy, Belgium, Austria, Switzerland and The United States. PharmaMar also wholly owns other companies: GENOMICA, a molecular diagnostics company; and Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.
Sylentis is a biotechnology company fully owned that develops innovative therapies harnessing the technology of post-transcriptional gene silencing or RNA interference (RNAi). Sylentis has developed an approach to efficiently design RNAi-based therapeutics that can be used to silence numerous disease-causing genes. We currently have a robust therapeutic program in ophthalmology with two candidates under development in Phase II and III studies for glaucoma (bamosiran) and ocular pain (SYL1001), respectively. Sylentis is also developing new products for the treatment of several eye diseases such as ocular allergies and retina diseases. To know more about us, please visit us at www.sylentis.com.